Electrocardiographic findings of the effects of beta-blockers

Andie Hartanto Djohan¹, MBBS, MRCP, Ching-Hui Sia¹,², MBBS, MRCP, William Kok-Fai Kong¹,², MD, Kian-Keong Poh¹,², MBBChir, FACC

CASE 1
CLINICAL PRESENTATION
An 85-year-old woman presented to the emergency department with drowsiness on a background of functional decline of two weeks' duration. Her medical history was significant for hypertension and hyperlipidaemia, for which she was on regular follow-up. Medications included amlodipine 10 mg OM (every morning), atenolol 100 mg OM, atorvastatin 20 mg ON, frusemide 40 mg OM, prazosin 0.5 mg BD (twice daily) and valsartan 160 mg OM. The patient was drowsy with Kussmaul breathing prior to a transient period of asystole noted on the cardiac monitor. Immediate resuscitation was performed with return of spontaneous circulation after 10 seconds.

Initial investigations showed decompensated metabolic acidosis (pH 7.14, partial pressure of carbon dioxide 24 mmHg, bicarbonate 8.4 mmol/L) with hyperkalaemia (6.9 mmol/L), for which she was treated with calcium gluconate, insulin and dextrose. What did her admission electrocardiogram (ECG) show (Fig. 1)?

ECG INTERPRETATION
Fig. 1 shows sinus node dysfunction with intermittent sinus P waves (black arrow) with first-degree atrioventricular block (double-headed arrow), as well as intermittent junctional escape beats (white arrow). Tall, tented T-waves (arrowhead) were observed in leads V2 and V3.

Fig. 2 shows a rhythm strip obtained from the cardiac monitor when the patient was paced transcutaneously. Pacing spikes are observed before each QRS complex (arrows).

CLINICAL COURSE
The patient’s hypotensive and bradycardic episodes persisted following resuscitation despite initiation and titration of intravenous dopamine to 20 mcg/kg/min. Further investigations
revealed acute kidney injury, with an elevated creatinine level of 853 µmol/L from a baseline of 65 µmol/L. The patient was then intubated for airway protection, started on inotropic support and administered intravenous glucagon. She was also commenced on transcutaneous pacing (TCP) at 70 beats per minute (bpm) (Fig. 2). The working diagnosis was cardiogenic shock secondary to the beta-blocker (BB) atenolol, which was attributed to acute kidney injury. The patient was then admitted to the intensive care unit, where continuous renal replacement therapy (CRRT) was initiated.

The patient’s intrinsic cardiac rhythm improved following two days of CRRT, with an improvement in her heart rate. The TCP backup pacing and inotropes were gradually weaned and stopped after four days, and the patient became haemodynamically stable without support. Atenolol was also stopped since admission.

CASE 2
CLINICAL PRESENTATION
A 53-year-old man with a significant medical history of Type 2 diabetes mellitus, hypertension, hyperlipidaemia, chronic kidney disease and ischaemic heart disease presented with non-ST elevation myocardial infarction on a background of septic shock and acute-on-chronic kidney injury/disease (AoCKD).

His medications included aspirin 100 mg OM, clopidogrel 75 mg OM, carvedilol 6.25 mg BD, atorvastatin 40 mg ON and frusemide 80 mg TDS (three times a day). The patient developed haemodynamically significant bradycardia despite being administered intravenous dopamine of 20 mcg/kg/min.

What does the ECG (Fig. 3) that was obtained at the onset of deterioration show?

ECG INTERPRETATION
Fig. 3 shows marked sinus bradycardia at a rate of 40 bpm, with first-degree heart block. There is a P wave (circles) preceding each QRS complex, and the PR interval (double-headed arrow) is prolonged at approximately 220 ms.

Fig. 4 shows a ventricular-paced rhythm, as evidenced by the small pacing spike (black arrows) just preceding its QRS complex (white arrowheads). We were able to localise the position of the pacing wire in the right ventricular (RV) apex owing to the left bundle branch block morphology of depolarisation on the precordial leads (black arrowheads) and negative QRS polarity on the inferior limb leads II, III and aVF (white arrows). The RV apex location of the transvenous pacing (TVP) tip was confirmed via chest radiograph, as observed in Fig. 5 (circle).

DISCUSSION
The patient remained haemodynamically unstable on intravenous infusion of dopamine of 20 mcg/kg/min and was started on TCP. This resulted in improvement of haemodynamics. Laboratory investigations revealed progression of AoCKD. Review of drug charts also revealed that the patient had been consistently administered carvedilol 6.25 mg BD during his inpatient stay. A diagnosis of haemodynamically significant bradycardia secondary to carvedilol retention on a background of poor renal clearance owing to AoCKD was established. The patient was sent to the coronary care unit for immediate TVP to augment cardiac output.

Pharmacokinetics
The pharmacokinetic properties of BBs can be broadly divided into lipophilic and hydrophilic drugs. Lipophilic drugs (e.g. metoprolol, propranolol and timolol) are absorbed from the enteral route but undergo extensive hepatic first-pass metabolism,
leading to low oral bioavailability (10%–30%). Hence, these drugs may accumulate in patients with reduced hepatic perfusion (e.g. elderly patients, or those with congestive cardiac failure or liver cirrhosis) (Table I). They have shorter elimination half-lives (1–5 hours) and may penetrate the blood-brain barrier, accounting for a greater incidence of central side effects.\(^{(9)}\)

Conversely, hydrophilic drugs (e.g. atenolol and esmolol) are absorbed in their entirety from the gastrointestinal tract and

<table>
<thead>
<tr>
<th>Drug</th>
<th>Hepatic metabolism (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propranolol</td>
<td>99</td>
</tr>
<tr>
<td>Timolol</td>
<td>80</td>
</tr>
<tr>
<td>Sotalol</td>
<td>40</td>
</tr>
<tr>
<td>Metoprolol</td>
<td>97</td>
</tr>
<tr>
<td>Atenolol</td>
<td>&lt; 10</td>
</tr>
</tbody>
</table>

![Fig. 3 Case 2: ECG at the onset of clinical deterioration.](image3.png)

![Fig. 4 Case 2: Electrocardiogram after transvenous pacing.](image4.png)
are renally excreted unchanged or as active metabolites. These drugs do not readily cross the blood-brain barrier and have longer elimination half-lives (6–24 hours), which are further prolonged in case of a reduction in glomerular filtration rate (GFR) (i.e. elderly individuals, patients with renal insufficiency) (Table II). (9,10)

BBs such as bisoprolol exhibit equal hepatic and renal clearance (balanced clearance), (9) while carvedilol has a low oral bioavailability owing to its extensive first-pass metabolism. It binds to plasma proteins and is eliminated hepatically. (11)

Adverse events related to beta-blocker use
In general, beta-adrenergic inhibitors are well tolerated. However, serious adverse events may still occur, especially when BBs are used in large doses, (9) as briefly mentioned below.

Cardiovascular
BBs may cause haemodynamically significant bradycardia and AV block via their negative chronotropic and inotropic properties. Further, BBs may reduce peripheral tissue perfusion owing to unopposed stimulation of vascular alpha-adrenoceptors because of blockade of vascular beta-adrenoceptors, leading to peripheral vasoconstriction, Raynaud’s phenomenon, impotence and deterioration of symptoms in patients with severe peripheral vascular disease. These side effects may be mitigated via the selection of agents with beta1-selectivity. BBs may also cause coronary vasospasm and ischaemia via their effect on increasing coronary vasomotor tone, again owing to unopposed alpha-adrenergic-mediated vasoconstriction. (9,11)

Finally, abrupt discontinuation of BBs following long-term therapy may lead to rebound symptoms such as arrhythmias and angina. (12)

Metabolic
In patients with diabetes mellitus, non-selective BBs may hide manifestations of hypoglycaemia such as tremor and tachycardia. Hence, beta1-selective agents are preferred in this vulnerable patient population.

Pulmonary
Beta2-adrenoceptors are responsible for bronchodilation of the pulmonary tree, and BBs may cause life-threatening bronchoconstriction, hyper-reactivity and increased airway resistance. As a result, BBs are relatively contraindicated in patients with asthma and bronchospastic chronic obstructive pulmonary disease. (13)

Effects on the central nervous system
Lipophilic BBs can cross the blood-brain barrier, leading to central nervous system (CNS) side effects such as fatigue, headache, insomnia, vivid dreams and depression. Clinicians may consider switching patients who experience these symptoms to a hydrophilic BB, where CNS penetration and side effects are markedly reduced. (14)

Management of symptomatic and/or haemodynamically unstable bradycardia
While sinus and junctional bradycardia are generally benign, extreme bradycardia from asystole or prolonged sinus arrest or AV blocks may render a patient symptomatic and/or lead to haemodynamic instability, which warrants acute management.

Pharmacological therapy
Pharmacological therapy can be immediately started with agents that increase the sinus heart rate or the escape rhythm, such as atropine, isoprenaline, dopamine, dobutamine and adrenaline. (15)

Transcutaneous pacing
TCP is an effective but underused modality owing to the discomfort it causes to the patient. It is suitable as an emergency life-saving therapy or as backup for infrequent pacing. In Case 1, TCP was initiated for haemodynamically significant bradycardia despite using the maximal dose of intravenous dopamine infusion. We opted for TCP instead of TVP, as the bradycardia of the patient was reversible with dialysis, thus avoiding the potential complications of TVP.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Half-life (hr)</th>
<th>Dosage in renal failure GFR (mL/min)</th>
<th>Dialysability</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal renal function</td>
<td>Uraemia</td>
<td>&gt; 50</td>
</tr>
<tr>
<td>Propranolol</td>
<td>2–4</td>
<td>2–3</td>
<td>Normal</td>
</tr>
<tr>
<td>Timolol</td>
<td>4–6</td>
<td>4</td>
<td>Normal</td>
</tr>
<tr>
<td>Sotalol</td>
<td>13–17</td>
<td>42</td>
<td>Normal</td>
</tr>
<tr>
<td>Metoprolol</td>
<td>2.5–4.5</td>
<td>2.5–4.5</td>
<td>Normal</td>
</tr>
<tr>
<td>Atenolol</td>
<td>6–9</td>
<td>127</td>
<td>Normal</td>
</tr>
</tbody>
</table>

GFR: glomerular filtration rate

![Table II. Properties of beta-blockers in relation to renal function.](image1)

Fig. 5 Case 2: Chest radiograph after transvenous pacing.
Transvenous pacing
Temporary TVP is an alternative to TCP but risks potentially serious complications such as infection, myocardial perforation and tamponade. The 2013 European Society of Cardiology guidelines on pacing suggest that TVP be used only when pharmacological therapy fails and that it be limited to cases of high-degree AV block without escape rhythm, life-threatening bradycardorrhiasms or in acute settings (acute myocardial infarction, drug toxicity or concomitant systemic infection). In Case 2, a transvenous pacing wire was inserted into the RV apex, as the patient remained haemodynamically compromised despite receiving the maximal dose of intravenous infusion of dopamine.

Haemodialysis
Lastly, haemodialysis may be considered when patients have been haemodynamically stabilised and if there is a dialysable culprit drug leading to bradycardia. In Case 1, the patient was initiated on CRRT immediately upon stabilisation of her clinical parameters. It is of utmost importance to identify any potentially reversible causes of an unstable bradycardia and address them, as evidenced by Case 1, where patients could be weaned off TCP following clearance of supratherapeutic levels of atenolol.

CONCLUSION
In conclusion, despite the vast therapeutic indications of BBs, their use is associated with potentially life-threatening risks. Prompt recognition of the signs and symptoms as well as the predisposing factor of BB-related toxicities and instituting appropriate emergency medical therapy are of utmost importance in the face of an ageing population with multiple comorbidities and polypharmacy.

REFERENCES
Question 1. Lipophilic beta-blockers include the following:
(a) Metoprolol
(b) Propranolol
(c) Timolol
(d) Atenolol

Question 2. The following drugs have predominantly renal clearance:
(a) Propranolol
(b) Metoprolol
(c) Atenolol
(d) Sotalol

Question 3. Indications for the use of beta-blockers include the following:
(a) Acute coronary syndrome
(b) Stable ischaemic heart disease
(c) Heart failure
(d) Supraventricular tachycardia

Question 4. Adverse events related to the use of beta-blockers include the following:
(a) Masking of hypoglycaemic symptoms (e.g. tremor, tachycardia)
(b) Impotence
(c) Peripheral vasoconstriction
(d) Coronary vasospasm and ischaemia

Question 5. Management of haemodynamically significant bradycardia includes the following:
(a) Atropine
(b) Dopamine
(c) Transcutaneous pacing
(d) Transvenous pacing

Doctor’s particulars:
Name in full: ___________________________________________  MCR no.: ___________________________________________
Specialty: ___________________________________________  Email: ___________________________________________